Abiopharma

🔍 French Glendon E. III (Executive)

Company: Pulmonx Corp (LUNG)

Report Date: 2026-06-01

Detailed Transactions and Holdings:

• Sold 4,171 shares of Common Stock at $1.54 per share (Direct)
  Date: 2026-06-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,230,140.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 38,467 shares of Common Stock at $1.54 per share (Direct)
  Date: 2026-06-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,191,673.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 13,511 shares of Common Stock at $1.57 per share (Direct)
  Date: 2026-06-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,178,162.00 | transaction_form_type: 4 | Footnotes: F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-06-01 | Code: H | nature_of_ownership: By trust | shares_owned_after: 918,198.00 | Footnotes: F4

Footnotes:

• F1: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on March 1, 2023.
• F2: Represents grant of RSUs payable solely in common stock of the Issuer that vests in equal quarterly installments over the three-year period following the date of grant of December 1, 2025.
• F3: Represents grant of RSUs payable solely in common stock of the Issuer that vests in equal quarterly installments over the three-year period following the date of grant of June 2, 2025.
• F4: The shares are held by the Glendon E French & Gayle French Trustees French Family Rev Trust UA DTD 08/29/2012, of which the reporting person and his spouse are trustees and beneficiaries.